The efficacy and safety of assessmentbased treatment models in patients with schizophrenia
Xi Lingyan1, Huang Xiuqin1, Zhang Suyun1, Li Ziyu1, Xu Congen1, Jin Guixing2
2019, 34(6):
530-534.
doi:10.3969/j.issn.1004-583X.2019.06.009
Asbtract
(
499 )
PDF (383KB)
(
194
)
HTML
Related Articles |
Metrics
Objective To investigate the efficacy and safety of an assessmentbased treatment model in patients with schizophrenia.Methods A total of 120 patients with schizophrenia who met the DSMV diagnostic criteria in our hospital from March 2017 to March 2018 were randomly divided into the study group and the control group, for each group 60 patients.The study group adopted an assessmentbased treatment model to take the secondgeneration antipsychotic risperidone tablets at a maximum dose of 46 mg/day. An assessment was performed at the end of the second week according to the negative and positive scales (PANSS). Should the rate of decreasebe less than 20%, replace it with olanzapine in a crossed way. The control group, however, adopted a conventional treatment plan, that is, administering the maximum dose of risperidone from the very beginning to the end of the study.PANSS and the Personal and Social Performance Scale (PSP) were evaluated before treatment, at the end of the 2nd weekend, the 4th weekend, and the 8th week to observe the patient's mental symptoms and social function, a sixmonth followup was carried out. Results In the study group, 9 cases were withdrawn due to intramuscular injection of haloperidol injection or other secondgeneration antipsychotic drugs, 1 case due to the adverse reactions, and 1 case due to the withdrawal of informed consent. In the control group, a total of 7 cases were withdrawn due to intramuscular injection of haloperidol injection or other the secondgeneration antipsychotic drugs, 3 cases due to adverse reactions, and 3 cases due to the withdrawl of the informed consent. At the end of the 4th and 8th week of treatment, the positive symptom score ［the 4th weekend (15.65±3.23 vs 18.04±2.50), the 8th weekend (13.35±2.90 vs 14.68±2.25)］, and the PANSS total score ［the 4th weekend (69.22±5.29 vs 72.04±5.53), the 8th weekend (58.33±4.44 vs 61.47±5.63)］ of the study group were significantly lower thanthose of the control group, and the difference was statistically significant (P<0.05);There was no significant difference in the negative symptoms between the two groups at any time point (P>0.05). The general psychopathological scores (31.94±2.40 vs 33.36±4.10) were only statistically significant at the 8th week of treatment (P<0.05), and that of the study group was even lower. At the 4th week and the 8th week of treatment, the PSP scores of the study group ［the 4th weekend (52.37±5.40 vs 49.36±4.91), the 8th weekend (61.33±5.81 vs 57.49±5.64)］ were significantly higher than that of the control group, and the differences were statistically significant (P<0.05); the PSP score (70.45±6.23 vs 65.83±5.97) of the study group was significantly higher than the other group during 6 months of followup (P<0.01).Conclusion The assessmentbased treatment models can control mental symptoms in patients with schizophrenia at an early stage and help improve their social function.